作者: Youzhi Li , Jifeng Liu , Chiang Jia Li , Harry Rogoff , Wei Li
DOI:
关键词:
摘要: The present invention relates to the use of a novel class cancer stem cell pathway (CSCP) inhibitors; methods using such compounds treat refractory, recurrent, or metastatic cancers; selective killing cells by with specific administration regimen; targeting inhibiting Stat3 pathway; in treatment conditions disorders mammal related aberrant activity; and processes for preparing intermediates thereof, pharmaceutical composition relevant compounds, these compounds.